Several next-generation ALK inhibitors, including alectinib, ceritinib, brigatinib, and lorlatinib, with activity against mechanisms of resistance to crizotinib, have since been developed and approved for use in ALK inhibitor-naive and -resistant NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.